No quarterly revenue total was found in ENDRA LIFE SCIENCES INC.'s SEC filings.
Endra Life Sciences Inc. (NDRA) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. Free cash flow was -$928,950. As of Jun 30, 2026 it held $1.7 million in cash and investments and $429,274 in total debt.
Revenue
—
Net income
$159,944
+113.0% vs year-ago quarter
Operating cash flow
$-927,560
+16.7% vs year-ago quarter
Free cash flow
$-928,950
+17.9% vs year-ago quarter
EPS
$0.06
+105.5% vs prior quarter
Dividend per share
None
Shares outstanding
1.50M
+99.2% vs year-ago quarter
Net cash
$1.31M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- NDRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ann Arbor, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1681682
- Former names
- Endra Inc. (until Sep 21, 2016)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.5M | -$2.2M | -$1.6M | -$1.4M | -$1.3M |
| Net income | $159,944 | -$1.3M | -$3.2M | -$1.6M | -$1.2M |
| Diluted EPS | $0.06 | -$1.09 | -$2.87 | -$2.10 | — |
| Operating cash flow | -$927,560 | -$1.1M | -$1.6M | -$1.2M | -$1.1M |
| Free cash flow | -$928,950 | — | -$1.6M | -$1.2M | -$1.1M |
| Total assets | $7.9M | $3.4M | $3.9M | $2.0M | $2.8M |
| Total liabilities | $1.6M | $1.7M | $1.6M | $1.8M | $1.3M |
| Stockholders' equity | $6.3M | $1.8M | $2.3M | $171,380 | $1.5M |
| Cash and investments | $1.7M | — | — | — | — |
| Total debt | $429,274 | $461,206 | $492,352 | $525,328 | $557,492 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 9, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Material agreement, Change in control, Regulation FD disclosure, Other events
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 25, 2026 | Jun 25, 2026 |
All 544 Endra Life Sciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.